Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsBruce Strober, MD, PhD, FAAD
Clinical ProfessorAbout
Research
Publications
2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity
Lebwohl M, Blauvelt A, Kartman C, Leatherwood C, Gordon K, Sattar N, Puig L, Merola J, Siu K, Wang R, Sun L, Leung A, Somani N, Rueda M, Cardoso A, Genovese M, Armstrong A, Strober B. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity. JAMA Dermatology 2026, e261753. PMID: 42139049, PMCID: PMC13179568, DOI: 10.1001/jamadermatol.2026.1753.Peer-Reviewed Original ResearchSummary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial
Langley R, Arkin L, Fiorillo L, Eichenfield L, Lebwohl M, Strober B, Sticherling M, Swanson L, Kokolakis G, Chaudhari S, Deignan C, Zhang Z, Paller A. Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial. Dermatology And Therapy 2026, 16: 2229-2232. PMID: 42133282, PMCID: PMC13219672, DOI: 10.1007/s13555-026-01714-0.Peer-Reviewed Original ResearchEnvudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review
Armstrong A, Krueger J, Strober B, Stein Gold L, Desai S, Muscianisi E, Klyachkin Y, Ucpinar S, Tilley M, Blauvelt A. Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review. Dermatology And Therapy 2026, 16: 2661-2673. PMID: 41934538, PMCID: PMC13237387, DOI: 10.1007/s13555-026-01727-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsReply to Woodie et al, “Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX”
Torres T, Blauvelt A, Strober B, van de Kerkhof P, Eakin G, Winthrop K, Gelfand J. Reply to Woodie et al, “Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX”. Journal Of The American Academy Of Dermatology 2026, 95: e71-e72. PMID: 41850622, DOI: 10.1016/j.jaad.2025.12.129.Commentaries, Editorials and LettersThe Role and Risks of Systemic Corticosteroids in Atopic Dermatitis: An Expert Consensus
Burshtein J, Bunick C, Vleugels R, Armstrong A, Golant A, Schlesinger T, Strober B, Song E, Stein Gold L, Shah M, DeBusk L, Rosenberg A, Bartley B, Zakria D, Lebwohl M. The Role and Risks of Systemic Corticosteroids in Atopic Dermatitis: An Expert Consensus. SKIN The Journal Of Cutaneous Medicine 2026, 10: s724. DOI: 10.25251/3j4scd05.Peer-Reviewed Original ResearchBimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials
Warren R, Strober B, Jullien D, Lebwohl M, Eyerich K, Langley R, Szilagyi B, Warham R, Armstrong A. Bimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials. SKIN The Journal Of Cutaneous Medicine 2026, 10: s758. DOI: 10.25251/0bnq3318.Peer-Reviewed Original ResearchApremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial
Langley R, Arkin L, Fiorillo L, Eichenfield L, Lebwohl M, Strober B, Sticherling M, Swanson L, Kokolakis G, Chaudhari S, Deignan C, Zhang Z, Paller A. Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial. Journal Of The American Academy Of Dermatology 2026, 94: 1777-1780. PMID: 41643746, DOI: 10.1016/j.jaad.2026.01.072.Peer-Reviewed Original ResearchIn Memoriam: Wayne Peter Francis Gulliver, MD, FRCPC (March 4, 1958-September 5, 2025)
Strober B. In Memoriam: Wayne Peter Francis Gulliver, MD, FRCPC (March 4, 1958-September 5, 2025). Journal Of The American Academy Of Dermatology 2026, 94: e139-e140. DOI: 10.1016/j.jaad.2025.10.060.Peer-Reviewed Original ResearchBrodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.
Lebwohl M, Krueger J, Koo J, Han G, Armstrong A, Strober B, Kircik L. Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence. Journal Of Drugs In Dermatology 2026, 25: 211-220. PMID: 41779761, DOI: 10.36849/jdd.9739.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThe role and risks of systemic corticosteroids in atopic dermatitis: an expert consensus
Burshtein J, Bunick C, Vleugels R, Armstrong A, K. Golant A, Schlesinger T, Strober B, Song E, Gold L, Shah M, DeBusk L, Rosenberg A, Bartley B, Zakria D, Lebwohl M. The role and risks of systemic corticosteroids in atopic dermatitis: an expert consensus. Archives Of Dermatological Research 2026, 318: 44. DOI: 10.1007/s00403-025-04502-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements